Nebulizer Delivery of Intranasal Scopolamine

Eligibility Criteria

• * Male or female
• * Adults age 21-49
• * Normal weight for body size, based on BMI table
• * General good health, as determined by a verbally provided medical history
• * Normal brief neurological exam
• * Renal and hepatic function within normal ranges
• * Able to provide written informed consent to participate
• * Drug allergies to scopolamine or other belladonna alkaloid
• * Use of medications within 1 week of starting the study
• * Use of an investigational drug within 30 days of starting the study
• * Tobacco smoking within the past year
• * Blood donation or significant blood loss within 30 days of starting the study
• * Significant gastrointestinal disorder (e.g. Crohn's Disease, ulcerative colitis, chronic constipation), asthma, glaucoma, prostate problems, urinary obstruction, or seizure disorders
• * History of alcohol or other drug abuse
• * Pregnancy or suspected pregnancy, or lactation (pregnancy will be confirmed with urine pregnancy testing prior to drug administration)
• * Consumption of grapefruit juice within 7 days of scopolamine (SCOP) administration
• * Nasal, nasal sinus, or nasal mucosa surgery within 90 days prior to study initiation
• * Other significant surgeries within 90 days
• * Significant deviated septum that blocks air flow in one nostril
• * Rhinitis, sinus infection, severe allergies, and other upper respiratory infections within 30 days prior to the study
• * Current use of an intranasal medication
• * Wheezing or other respiratory problem
• * Unable to consent
• * Prisoner